Keyphrases
Weight Loss
100%
Acne
92%
Liraglutide
80%
Confidence Interval
76%
Placebo
70%
Glucagon-like
66%
A1 Receptor
66%
Receptor Agonist
66%
Population-based Study
64%
Milk Consumption
60%
Older Adults
50%
Low-calorie Diet
50%
Cardiac Electrophysiology
50%
Calcium Concentration
50%
Mendelian Randomization
50%
Calcium Magnesium
50%
Systematic Meta-analysis
50%
Electrocardiographic Changes
50%
Cutibacterium Acnes (C. acnes)
50%
Ventricular Repolarization
50%
Psoriasis
50%
Magnesium Concentration
50%
Potassium Concentration
50%
Dairy Consumption
50%
Benefit-risk Assessment
50%
GLP-1 Receptor Agonist
50%
Acne Vulgaris
50%
Randomized Controlled Trial
50%
Hidradenitis Suppurativa
50%
Preadolescent children
50%
Lactase Persistence
50%
Long QT Interval
50%
Meta-analysis
50%
Liraglutide 3.0 Mg
43%
Dairy
40%
Odds Ratio
34%
Physiologically Relevant
33%
Antihypertensive Drugs
33%
RR Interval
33%
Electrolyte Concentration
33%
Electrolyte
33%
Magnesium
33%
Lifestyle Modification
30%
Semaglutide
30%
PR Interval
27%
Cardiovascular Mortality
27%
Clinically Significant
26%
Obesity
26%
QT Interval
23%
Comorbidity
20%
Medicine and Dentistry
Glucagon-Like Peptide-1 Agonist
100%
Liraglutide
100%
Acneiform Eruption
100%
Placebo
75%
Population Research
65%
Adult Acne
50%
Acne Vulgaris
50%
Meta-Analysis
50%
Ibuprofen
50%
ECG Abnormality
50%
Psoriasis
50%
Magnesium
50%
Lactase Persistence
50%
Mendelian Randomization Analysis
50%
Systematic Review
50%
Adolescence
50%
Very Low Calorie Diet
50%
Isotopes of Calcium
50%
Hidradenitis Suppurativa
50%
Repolarization
50%
Randomized Controlled Trial
50%
QT Prolongation
40%
Semaglutide
37%
Lifestyle Modification
37%
Odds Ratio
36%
Cardiac Electrophysiology
30%
Electrocardiogram
28%
Body Mass Index
26%
Body Weight Loss
25%
Comorbidity
25%
Antiobesity Drugs
25%
Body Weight
25%
PR Interval
21%
Antihypertensive Drug
20%
RR Interval
20%
Cardiovascular System
15%
QRS Interval
15%
Resting Heart Rate
15%
Suburban Population
15%
